Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

South Korea flag South Korea · Delayed Price · Currency is KRW
51,500
-1,400 (-2.65%)
Jul 20, 2026, 3:30 PM KST
Market Cap1.62T +44.9%
Revenue (ttm)7.97B -5.2%
Net Income-36.93B
EPS-1,222.89
Shares Out 30.57M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume115,736
Open51,000
Previous Close52,900
Day's Range50,700 - 53,600
52-Week Range35,850 - 179,900
Beta1.11
Analystsn/a
Price Targetn/a
Earnings DateAug 11, 2026

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2002
Employees 18
Stock Exchange KOSDAQ
Ticker Symbol 140410
Full Company Profile

Financial Performance

In 2025, Mezzion Pharma's revenue was 7.91 billion, a decrease of -8.15% compared to the previous year's 8.61 billion. Losses were -34.93 billion, 79.3% more than in 2024.

Financial Statements

News

Mezzion Pharma's Udenafil Shows Promise for Fontan-Related Liver Disease

Mezzion Pharma's Udenafil Shows Promise for Fontan-Related Liver Disease

3 days ago - GuruFocus